{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-24-000037","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.423878+00:00","generated_at":"2026-06-04T04:50:49.862262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering","bullets":["Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).","Cash and equivalents $1.8M as of Dec 31, 2023; subsequent Feb 2024 public offering raised $5.5M.","Phase 2a biomarker study for lead IPF drug GRI-0621 ongoing; interim data H1 2024, topline H2 2024.","GRI-0803 for SLE completing IND-enabling studies; IND filing on track for H1 2024.","Received notice of allowance for Canadian patent covering proprietary NKT cell modulators."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-24-000037","json":"https://secwatch.observer/filing/0001824293-24-000037.json","markdown":"https://secwatch.observer/filing/0001824293-24-000037.md","text":"https://secwatch.observer/filing/0001824293-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/0001824293-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/val-20240401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:50:49.862262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bab25b857591907a4fc6ebc49851cd7cfc4fac31","claim":"GRI Bio, Inc. reported financial results for fiscal year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, GRI Bio, Inc. (the Company) issued a press release announcing its financial results for the year ended December 31, 2023, and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429324000037/0001824293-24-000037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}